Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings

Infect Dis Clin North Am. 2018 Jun;32(2):253-268. doi: 10.1016/j.idc.2018.02.002.

Abstract

Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease.

Keywords: Cirrhosis; Comorbidities; Direct-acting antiviral; Hepatitis C; Mortality; Real-world cohort; Sustained viral response.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • Cohort Studies
  • Female
  • Hepacivirus / drug effects
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / mortality*
  • Humans
  • Liver Cirrhosis / drug therapy*
  • Liver Cirrhosis / mortality*
  • Liver Cirrhosis / pathology
  • Male
  • Middle Aged
  • Observational Studies as Topic
  • Patient Reported Outcome Measures*
  • Ribavirin / therapeutic use
  • Time Factors
  • Young Adult

Substances

  • Antiviral Agents
  • Ribavirin